Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Psychosom Med, 66(2), 276-82
GLP-1 Drug Repurposing for Addiction Disorders Hampered by High Costs and Legal Hurdles Don Tracy, Associate Editor Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how regulatory, patent, and reimbursement challenges are slowing venture investment in GLP-1 and psychedelic addiction therapies
Promoters claim peptides boost energy, speed recovery and healing, and more
Others find it mildly uncomfortable but tolerable
Your provider may recommend testing and treatment to diagnose and manage the underlying condition
US$ 24.00
US$ 22.68
US$ 26.28
US$ 21.99
US$ 21.33
US$ 26.34
US$ 21.29
US$ 25.83
